BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci 2017;18:E441. [PMID: 28218669 DOI: 10.3390/ijms18020441] [Cited by in Crossref: 232] [Cited by in F6Publishing: 242] [Article Influence: 46.4] [Reference Citation Analysis]
Number Citing Articles
1 Evangelista TCS, López Ó, Puerta A, Fernandes MX, Ferreira SB, Padrón JM, Fernández-Bolaños JG, Sydnes MO, Lindbäck E. A hybrid of 1-deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE). J Enzyme Inhib Med Chem 2022;37:2395-402. [PMID: 36065944 DOI: 10.1080/14756366.2022.2117912] [Reference Citation Analysis]
2 Pehrsson M, Heikkinen H, Wartiovaara-kautto U, Mäntylahti S, Bäckström P, Lassenius MI, Uusi-rauva K, Carpén O, Elomaa K. Screening for potential undiagnosed Gaucher disease patients: Utilisation of the Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS) in conjunction with electronic health record data, tissue specimens, and small nucleotide polymorphism (SNP) genotype data available in Finnish biobanks. Molecular Genetics and Metabolism Reports 2022;33:100911. [DOI: 10.1016/j.ymgmr.2022.100911] [Reference Citation Analysis]
3 Ridova N, Trajkova S, Chonevska B, Stojanoski Z, Ivanovski M, Popova-Labachevska M, Stojanovska-Jakimovska S, Filipche V, Sofijanova A, Panovska-Stavridis I. Gaucher disease in North Macedonia: Unexpected prevalence of the N370S GBA1 allele with attenuated disease expression. Mol Genet Metab Rep 2022;32:100895. [PMID: 35845720 DOI: 10.1016/j.ymgmr.2022.100895] [Reference Citation Analysis]
4 Zhao H, Song S, Ma J, Yan Z, Xie H, Feng Y, Che S. CD47 as a promising therapeutic target in oncology. Front Immunol 2022;13:757480. [DOI: 10.3389/fimmu.2022.757480] [Reference Citation Analysis]
5 Zou Y, Pei J, Wang Y, Chen Q, Sun M, Kang L, Zhang X, Zhang L, Gao X, Lin Z. The Deficiency of SCARB2/LIMP-2 Impairs Metabolism via Disrupted mTORC1-Dependent Mitochondrial OXPHOS. IJMS 2022;23:8634. [DOI: 10.3390/ijms23158634] [Reference Citation Analysis]
6 Arévalo NB, Lamaizon CM, Cavieres VA, Burgos PV, Álvarez AR, Yañez MJ, Zanlungo S. Neuronopathic Gaucher disease: Beyond lysosomal dysfunction. Front Mol Neurosci 2022;15:934820. [DOI: 10.3389/fnmol.2022.934820] [Reference Citation Analysis]
7 Iaccarino Idelson P, Speranza E, Marra M, Pasanisi F, Sammarco R, Galletti F, Strazzullo P, Barbato A. Evaluation of the Nutritional Status of Gaucher Disease Type I Patients under Enzyme Replacement Treatment. Nutrients 2022;14:3180. [DOI: 10.3390/nu14153180] [Reference Citation Analysis]
8 Alnaghy E, Razek AA, Abdelhalim E. Pre- and post-therapeutic evaluation of liver and spleen in type I and type III Gaucher's disease using diffusion tensor imaging. Abdom Radiol (NY) 2022. [PMID: 35867132 DOI: 10.1007/s00261-022-03602-5] [Reference Citation Analysis]
9 Wang M, Li F, Zhang J, Lu C, Kong W. Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis. J Pediatr Hematol Oncol 2022. [PMID: 35867706 DOI: 10.1097/MPH.0000000000002506] [Reference Citation Analysis]
10 Deen MC, Zhu Y, Gros C, Na N, Gilormini P, Shen DL, Bhosale S, Anastasi N, Wang R, Shan X, Harde E, Jagasia R, Lynn FC, Vocadlo DJ. A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells. Proc Natl Acad Sci U S A 2022;119:e2200553119. [DOI: 10.1073/pnas.2200553119] [Reference Citation Analysis]
11 Leonart LP, Fachi MM, Böger B, Silva MRD, Szpak R, Lombardi NF, Pedroso MLA, Pontarolo R. A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease. Ann Pharmacother 2022;:10600280221108443. [PMID: 35815393 DOI: 10.1177/10600280221108443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Huang Y, Zheng Y, Zhang C, Zhong S, Hussein AF. Ultrasound Assessment of the Relevance of Liver, Spleen, and Kidney Dimensions with Body Parameters in Adolescents. Computational and Mathematical Methods in Medicine 2022;2022:1-7. [DOI: 10.1155/2022/9150803] [Reference Citation Analysis]
13 Kong W, Lu C, Ding Y, Meng Y. Update of treatment for Gaucher disease. European Journal of Pharmacology 2022;926:175023. [DOI: 10.1016/j.ejphar.2022.175023] [Reference Citation Analysis]
14 Guo JN, Guan M, Jiang N, Li N, Li YJ, Zhang J, Ma D. Establishment and Phenotypic Analysis of the Novel Gaucher Disease Mouse Model With the Partially Humanized Gba1 Gene and F213I Mutation. Front Genet 2022;13:892457. [PMID: 35711931 DOI: 10.3389/fgene.2022.892457] [Reference Citation Analysis]
15 Aries C, Lohmöller B, Tiede S, Täuber K, Hartmann G, Rudolph C, Muschol N. Promising Effect of High Dose Ambroxol Treatment on Neurocognition and Motor Development in a Patient With Neuropathic Gaucher Disease 2. Front Neurol 2022;13:907317. [DOI: 10.3389/fneur.2022.907317] [Reference Citation Analysis]
16 Torralba-cabeza M, Morado-arias M, Pijierro-amador A, Fernández-canal M, Villarrubia-espinosa J. Recommendations for oral treatment for adult patients with type 1 Gaucher disease. Revista Clínica Española (English Edition) 2022. [DOI: 10.1016/j.rceng.2022.02.008] [Reference Citation Analysis]
17 Sawada T, Kido J, Sugawara K, Yoshida S, Matsumoto S, Shimazu T, Matsushita Y, Inoue T, Hirose S, Endo F, Nakamura K. Newborn screening for Gaucher disease in Japan. Molecular Genetics and Metabolism Reports 2022;31:100850. [DOI: 10.1016/j.ymgmr.2022.100850] [Reference Citation Analysis]
18 Lunev E, Karan A, Egorova T, Bardina M. Adeno-Associated Viruses for Modeling Neurological Diseases in Animals: Achievements and Prospects. Biomedicines 2022;10:1140. [DOI: 10.3390/biomedicines10051140] [Reference Citation Analysis]
19 Ruiz-Barrio I, Horta-Barba A, Illán-Gala I, Kulisevsky J, Pagonabarraga J. Genotype-Phenotype Correlation in Progressive Supranuclear Palsy Syndromes: Clinical and Radiological Similarities and Specificities. Front Neurol 2022;13:861585. [PMID: 35557621 DOI: 10.3389/fneur.2022.861585] [Reference Citation Analysis]
20 Byrne FL, Olzomer EM, Lolies N, Hoehn KL, Wegner MS. Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma. Int J Mol Sci 2022;23:4477. [PMID: 35562868 DOI: 10.3390/ijms23094477] [Reference Citation Analysis]
21 Ung J, Tan S, Fox TE, Shaw JJ, Vass LR, Costa-pinheiro P, Garrett-bakelman FE, Keng MK, Sharma A, Claxton DF, Levine RL, Tallman MS, Cabot MC, Kester M, Feith DJ, Loughran TP. Harnessing the power of sphingolipids: Prospects for acute myeloid Leukemia. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100950] [Reference Citation Analysis]
22 Ibrahimi MA, Hakimi T, Halimi SA. Beta-Thalassemia major with Gaucher disease. International Journal of Surgery Open 2022. [DOI: 10.1016/j.ijso.2022.100460] [Reference Citation Analysis]
23 Zheng W, Fan D. Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications. Front Aging Neurosci 2022;14:851135. [DOI: 10.3389/fnagi.2022.851135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Mohamed FE, Ali A, Al-tenaiji A, Al-jasmi A, Al-jasmi F. A Type 3 Gaucher-Like Disease Due To Saposin C Deficiency in Two Emirati Families Caused by a Novel Splice Site Variant in the PSAP Gene. J Mol Neurosci. [DOI: 10.1007/s12031-022-01987-y] [Reference Citation Analysis]
25 Berdowska I, Matusiewicz M, Krzystek-korpacka M. HDL Accessory Proteins in Parkinson’s Disease—Focusing on Clusterin (Apolipoprotein J) in Regard to Its Involvement in Pathology and Diagnostics—A Review. Antioxidants 2022;11:524. [DOI: 10.3390/antiox11030524] [Reference Citation Analysis]
26 Murray SJ, Mitchell NL. The Translational Benefits of Sheep as Large Animal Models of Human Neurological Disorders. Front Vet Sci 2022;9:831838. [PMID: 35242840 DOI: 10.3389/fvets.2022.831838] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ersoy M, Pişkinpaşa H. Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy. J Pediatr Endocrinol Metab 2022. [PMID: 35245971 DOI: 10.1515/jpem-2021-0664] [Reference Citation Analysis]
28 Lelieveld LT, Gerhardt S, Maas S, Zwiers KC, de Wit C, Beijk EH, Ferraz MJ, Artola M, Meijer AH, Tudorache C, Salvatori D, Boot RG, Aerts JM. Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish. Journal of Lipid Research 2022. [DOI: 10.1016/j.jlr.2022.100199] [Reference Citation Analysis]
29 Weinreb NJ, Goker-alpan O, Kishnani PS, Longo N, Burrow TA, Bernat JA, Gupta P, Henderson N, Pedro H, Prada CE, Vats D, Pathak RR, Wright E, Ficicioglu C. The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.03.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Davighi MG, Clemente F, Matassini C, Cardona F, Nielsen MB, Goti A, Morrone A, Paoli P, Cacciarini M. Photoswitchable inhibitors of human β-glucocerebrosidase. Org Biomol Chem 2022;20:1637-41. [PMID: 35107482 DOI: 10.1039/d1ob02159a] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Chettab K, Matera EL, Lafond M, Coralie D, Favin-Lévêque C, Goy C, Strakhova R, Mestas JL, Lafon C, Dumontet C. Proof of Concept: Protein Delivery into Human Erythrocytes Using Stable Cavitation. Mol Pharm 2022. [PMID: 35147436 DOI: 10.1021/acs.molpharmaceut.1c00907] [Reference Citation Analysis]
32 Kelkel MA, Boutin M, Curado F, Bauer P, Beauregard-Lacroix É, Mercier FE, Maranda B, Menkovic I, Martineau T, Auray-Blais C. Lysosphingolipid urine screening test using mass spectrometry for the early detection of lysosomal storage disorders. Bioanalysis 2022. [PMID: 35118880 DOI: 10.4155/bio-2021-0259] [Reference Citation Analysis]
33 Menkovic I, Boutin M, Alayoubi A, Curado F, Bauer P, Mercier FE, Rivard GÉ, Auray-Blais C. Quantitation of a plasma biomarker profile for the early detection of Gaucher disease type 1 patients. Bioanalysis 2022. [PMID: 35118875 DOI: 10.4155/bio-2021-0242] [Reference Citation Analysis]
34 Uthailak N, Kajiura H, Misaki R, Fujiyama K. Production of recombinant β-glucocerebrosidase in wild-type and glycoengineered transgenic Nicotiana benthamiana root cultures with different N-glycan profiles. Journal of Bioscience and Bioengineering 2022. [DOI: 10.1016/j.jbiosc.2022.01.002] [Reference Citation Analysis]
35 Wen Tan SL, Israeli E, Ericksen RE, Chow PK, Han W. The altered lipidome of hepatocellular carcinoma. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Lin WD, Tsai FJ. Genetic Analysis of Acid β-Glucosidase in Patients with Multiple Myeloma from Central Taiwan: A Small-Cohort Case-Control Study. Biomed Hub 2021;6:138-44. [PMID: 35083226 DOI: 10.1159/000519704] [Reference Citation Analysis]
37 Roh J, Subramanian S, Weinreb NJ, Kartha RV. Gaucher disease – more than just a rare lipid storage disease. J Mol Med. [DOI: 10.1007/s00109-021-02174-z] [Reference Citation Analysis]
38 Bo RX, Li YY, Zhou TT, Chen NH, Yuan YH. The neuroinflammatory role of glucocerebrosidase in Parkinson's disease. Neuropharmacology 2022;207:108964. [PMID: 35065083 DOI: 10.1016/j.neuropharm.2022.108964] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Levine SM, Tsau S. Substrate Reduction Therapy for Krabbe Disease: Exploring the Repurposing of the Antibiotic D-Cycloserine. Front Pediatr 2022;9:807973. [DOI: 10.3389/fped.2021.807973] [Reference Citation Analysis]
40 Tsitsi P, Markaki I, Waldthaler J, Machaczka M, Svenningsson P. Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease. JIMD Rep 2022;63:93-100. [PMID: 35028274 DOI: 10.1002/jmd2.12262] [Reference Citation Analysis]
41 Francelle L, Mazzulli JR. Neuroinflammation in aucher disease, neuronal ceroid lipofuscinosis, and commonalities with Parkinson’s disease. Brain Research 2022. [DOI: 10.1016/j.brainres.2022.147798] [Reference Citation Analysis]
42 Caso-gonzález A, Núñez-rodríguez J, Nebot-villacampa M, González-pérez Y, Marín-gorricho R, Leralta-gonzález C, Obaldia-alaña C. Clinical experience with orphan drugs for rare metabolic diseases. Anales de Pediatría (English Edition) 2022. [DOI: 10.1016/j.anpede.2020.09.014] [Reference Citation Analysis]
43 Cabrera-Reyes F, Parra-Ruiz C, Yuseff MI, Zanlungo S. Alterations in Lysosome Homeostasis in Lipid-Related Disorders: Impact on Metabolic Tissues and Immune Cells. Front Cell Dev Biol 2021;9:790568. [PMID: 34957117 DOI: 10.3389/fcell.2021.790568] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Kishnani PS, Al-Hertani W, Balwani M, Göker-Alpan Ö, Lau HA, Wasserstein M, Weinreb NJ, Grabowski G. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab 2021:S1096-7192(21)01194-X. [PMID: 34972655 DOI: 10.1016/j.ymgme.2021.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Giraldo P, Andrade-Campos M. Novel Management and Screening Approaches for Haematological Complications of Gaucher's Disease. J Blood Med 2021;12:1045-56. [PMID: 34908889 DOI: 10.2147/JBM.S279756] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Esteban O, Torralba MA, Olivera S, Martinez M, Montes P, Marco S, Ascaso J. New correlations between ocular parameters and disease severity in Spanish patients with Gaucher's disease Type I. PLoS One 2021;16:e0260241. [PMID: 34871300 DOI: 10.1371/journal.pone.0260241] [Reference Citation Analysis]
47 Sagara R, Ishigaki M, Otsuka M, Murayama K, Ida H, Fernandez J. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan. Orphanet J Rare Dis 2021;16:502. [PMID: 34863216 DOI: 10.1186/s13023-021-02119-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Borie-Guichot M, Tran ML, Génisson Y, Ballereau S, Dehoux C. Pharmacological Chaperone Therapy for Pompe Disease. Molecules 2021;26:7223. [PMID: 34885805 DOI: 10.3390/molecules26237223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 van Gool R, Tucker-Bartley A, Yang E, Todd N, Guenther F, Goodlett B, Al-Hertani W, Bodamer OA, Upadhyay J. Targeting neurological abnormalities in lysosomal storage diseases. Trends Pharmacol Sci 2021:S0165-6147(21)00222-4. [PMID: 34844772 DOI: 10.1016/j.tips.2021.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Rowland RJ, Chen Y, Breen I, Wu L, Offen WA, Beenakker TJ, Su Q, van den Nieuwendijk AMCH, Aerts JMFG, Artola M, Overkleeft HS, Davies GJ. Design, Synthesis and Structural Analysis of Glucocerebrosidase Imaging Agents. Chemistry 2021;27:16377-88. [PMID: 34570911 DOI: 10.1002/chem.202102359] [Reference Citation Analysis]
51 Shola-Dare O, Bailess S, Flores CC, Vanderheyden WM, Gerstner JR. Glitazone Treatment Rescues Phenotypic Deficits in a Fly Model of Gaucher/Parkinson's Disease. Int J Mol Sci 2021;22:12740. [PMID: 34884544 DOI: 10.3390/ijms222312740] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Magnusen AF, Rani R, McKay MA, Hatton SL, Nyamajenjere TC, Magnusen DNA, Köhl J, Grabowski GA, Pandey MK. C-X-C Motif Chemokine Ligand 9 and Its CXCR3 Receptor Are the Salt and Pepper for T Cells Trafficking in a Mouse Model of Gaucher Disease. Int J Mol Sci 2021;22:12712. [PMID: 34884512 DOI: 10.3390/ijms222312712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Mammadova A, Mermer A, Kocabaş F. Screening of the small molecule library of Meinox enables the identification of anticancer compounds in pathologically distinct cancers. Turk J Biol 2021;45:633-43. [PMID: 34803460 DOI: 10.3906/biy-2104-14] [Reference Citation Analysis]
54 Barootes HC, Prasad C, Rupar CA, Ashok D. An Unexpected Finding of Hepatosplenomegaly in a Pediatric Patient. Clin Pediatr (Phila) 2021;:99228211059668. [PMID: 34789027 DOI: 10.1177/00099228211059668] [Reference Citation Analysis]
55 Ivanova MM, Dao J, Kasaci N, Adewale B, Nazari S, Noll L, Fikry J, Sanati AH, Goker-Alpan O. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease. PLoS One 2021;16:e0247211. [PMID: 34695170 DOI: 10.1371/journal.pone.0247211] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Messelodi D, Bertuccio SN, Indio V, Strocchi S, Taddia A, Serravalle S, Bandini J, Astolfi A, Pession A. iPSC-Derived Gaucher Macrophages Display Growth Impairment and Activation of Inflammation-Related Cell Death. Cells 2021;10:2822. [PMID: 34831047 DOI: 10.3390/cells10112822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Tantawy AAG, Adly AAM, Atif HM, Madkour SS, Salah NY. Abdominal lymphadenopathy in children with Gaucher disease: Relation to disease severity and glucosylsphingosine. Pediatr Hematol Oncol 2021;:1-14. [PMID: 34668825 DOI: 10.1080/08880018.2021.1989098] [Reference Citation Analysis]
58 Higgins AL, Toffoli M, Mullin S, Lee CY, Koletsi S, Avenali M, Blandini F, Schapira AH. The remote assessment of parkinsonism supporting ongoing development of interventions in Gaucher disease. Neurodegener Dis Manag 2021. [PMID: 34666501 DOI: 10.2217/nmt-2021-0032] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
59 D'Amore S, Page K, Donald A, Taiyari K, Tom B, Deegan P, Tan CY, Poole K, Jones SA, Mehta A, Hughes D, Sharma R, Lachmann RH, Chakrapani A, Geberhiwot T, Santra S, Banka S, Cox TM; MRC GAUCHERITE Consortium. In-depth phenotyping for clinical stratification of Gaucher disease. Orphanet J Rare Dis 2021;16:431. [PMID: 34649574 DOI: 10.1186/s13023-021-02034-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Lee CY, Menozzi E, Chau KY, Schapira AHV. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes. J Neurochem 2021;159:826-39. [PMID: 34618942 DOI: 10.1111/jnc.15524] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
61 Senkevich K, Rudakou U, Gan-Or Z. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology 2021;202:108822. [PMID: 34626666 DOI: 10.1016/j.neuropharm.2021.108822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
62 Kannauje PK, Pandit V, Wasnik PN, Gupta AK, Venkatesan N. Gaucher's Disease in an Adult Female: A Rare Entity. Cureus 2021;13:e17318. [PMID: 34557364 DOI: 10.7759/cureus.17318] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Uşurelu N, Blăniţă D, Boiciuc C, Hlistun V, Egorov V, Popovici E, Gnatcova E, Stamati A, Oglindă A, Revenco N, Gladun S, Ţurea V. Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report. Med Pharm Rep 2021;94:S57-60. [PMID: 34527913 DOI: 10.15386/mpr-2232] [Reference Citation Analysis]
64 Serfecz JC, Saadin A, Santiago CP, Zhang Y, Bentzen SM, Vogel SN, Feldman RA. C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages. Int J Mol Sci 2021;22:9912. [PMID: 34576075 DOI: 10.3390/ijms22189912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
65 Gumus E, Karhan AN, Hizarcioglu-Gulsen H, Demir H, Ozen H, Saltik Temizel IN, Dokmeci Emre S, Yuce A. Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience. Eur J Med Genet 2021;64:104339. [PMID: 34500086 DOI: 10.1016/j.ejmg.2021.104339] [Reference Citation Analysis]
66 Parolo S, Tomasoni D, Bora P, Ramponi A, Kaddi C, Azer K, Domenici E, Neves-Zaph S, Lombardo R. Reconstruction of the Cytokine Signaling in Lysosomal Storage Diseases by Literature Mining and Network Analysis. Front Cell Dev Biol 2021;9:703489. [PMID: 34490253 DOI: 10.3389/fcell.2021.703489] [Reference Citation Analysis]
67 Starosta RT, Siebert M, Vairo FPE, Costa BLL, Ponzoni CT, Schwartz IVD, Cerski CTS. Histomorphometric analysis of liver biopsies of treated patients with Gaucher disease type 1. Autops Case Rep 2021;11:e2021306. [PMID: 34458174 DOI: 10.4322/acr.2021.306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Gao H, Fan A. Green synthesis of 1,5-dideoxy-1,5-imino-ribitol and 1,5-dideoxy-1,5-imino-DL-arabinitol from natural D-sugars over Au/Al2O3 and SO42-/Al2O3 catalysts. Sci Rep 2021;11:16928. [PMID: 34413372 DOI: 10.1038/s41598-021-96231-9] [Reference Citation Analysis]
69 Mulroy E, Baschieri F, Magrinelli F, Latorre A, Cortelli P, Bhatia KP. Movement Disorders and Liver Disease. Mov Disord Clin Pract 2021;8:828-42. [PMID: 34401403 DOI: 10.1002/mdc3.13238] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Rosanio FM, D'Acunzo I, Mozzillo F, Di Pinto R, Tornincasa C, Amabile S, Piccirillo A, Roma V, Giordano L. Perinatal-lethal Gaucher disease presenting with blueberry muffin lesions. Pediatr Dermatol 2021. [PMID: 34339539 DOI: 10.1111/pde.14735] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Pinti E, Nemeth K, Staub K, Lengyel A, Fekete G, Haltrich I. Diagnostic difficulties and possibilities of NF1-like syndromes in childhood. BMC Pediatr 2021;21:331. [PMID: 34325699 DOI: 10.1186/s12887-021-02791-0] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
72 Ponomarev RV, Lukina EA. Gaucher disease: achievements and prospects. Terapevticheskii arkhiv 2021;93:830-6. [DOI: 10.26442/00403660.2021.07.200912] [Reference Citation Analysis]
73 Hershkop E, Bergman I, Kurolap A, Dally N, Feldman HB. Non-immune Hemolysis in Gaucher Disease and Review of the Literature. Rambam Maimonides Med J 2021;12. [PMID: 34270405 DOI: 10.5041/RMMJ.10446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Oliveira de Santana QL, Santos Evangelista TC, Imhof P, Ferreira SB, Fernández-Bolaños JG, Sydnes MO, Lopéz Ó, Lindbäck E. Tacrine-sugar mimetic conjugates as enhanced cholinesterase inhibitors. Org Biomol Chem 2021;19:2322-37. [PMID: 33645607 DOI: 10.1039/d0ob02588g] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
75 Bjelobrk M, Lakocevic M, Damjanovic S, Petakov M, Petrovic M, Bosnic Z, Arena R, Popovic D. Cardiopulmonary assessment of patients diagnosed with Gaucher's disease type I. Mol Genet Genomic Med 2021;9:e1757. [PMID: 34275192 DOI: 10.1002/mgg3.1757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Verma J, Roy P, Thomas DC, Dua Puri R, Verma IC. Levels of Lyso GL-1 in Gaucher and Lyso GL-3 in Fabry patients from India: Diagnostic aids for these lysosomal storage disorders. Clin Chim Acta 2021;521:177-90. [PMID: 34280392 DOI: 10.1016/j.cca.2021.07.017] [Reference Citation Analysis]
77 Paskulin LD, Starosta RT, Bertholdo D, Vairo FP, Vedolin L, Schwartz IVD. Bone marrow burden score is not useful as a follow-up parameter in stable patients with type 1 Gaucher disease after 5 years of treatment. Blood Cells Mol Dis 2021;90:102591. [PMID: 34242856 DOI: 10.1016/j.bcmd.2021.102591] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Ramaswami U, Mengel E, Berrah A, AlSayed M, Broomfield A, Donald A, Seif El Dein HM, Freisens S, Hwu WL, Peterschmitt MJ, Yoo HW, Abdelwahab M. Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma. Mol Genet Metab 2021;133:335-44. [PMID: 34229967 DOI: 10.1016/j.ymgme.2021.06.009] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
79 Menozzi E, Schapira AHV. Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Front Neurol 2021;12:694764. [PMID: 34248830 DOI: 10.3389/fneur.2021.694764] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
80 Abeliovich A, Hefti F, Sevigny J. Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations. J Parkinsons Dis 2021. [PMID: 34151863 DOI: 10.3233/JPD-212739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
81 Pająk R, Mendela E, Będkowska N, Paprocka J. Update on Neuropathies in Inborn Errors of Metabolism. Brain Sci 2021;11:763. [PMID: 34201281 DOI: 10.3390/brainsci11060763] [Reference Citation Analysis]
82 Uthailak N, Kajiura H, Misaki R, Fujiyama K. Transient Production of Human β-Glucocerebrosidase With Mannosidic-Type N-Glycan Structure in Glycoengineered Nicotiana benthamiana Plants. Front Plant Sci 2021;12:683762. [PMID: 34163514 DOI: 10.3389/fpls.2021.683762] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
83 Lazea C, Bucerzan S, Al-Khzouz C, Zimmermann A, Vesa ȘC, Nașcu I, Creț V, Crișan M, Asăvoaie C, Miclea D, Grigorescu-Sido P. Cardiac Manifestations in a Group of Romanian Patients with Gaucher Disease Type 1 (a Monocentric Study). Diagnostics (Basel) 2021;11:989. [PMID: 34072542 DOI: 10.3390/diagnostics11060989] [Reference Citation Analysis]
84 Wang XM, Zeng P, Fang YY, Zhang T, Tian Q. Progranulin in neurodegenerative dementia. J Neurochem 2021;158:119-37. [PMID: 33930186 DOI: 10.1111/jnc.15378] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
85 Basgalupp SP, Donis KC, Siebert M, E Vairo FP, Artigalas O, de Camargo Pinto LL, Behringer S, Spiekerkoetter U, Hannibal L, Schwartz IVD. Elevated holo-transcobalamin in Gaucher disease type II: A case report. Am J Med Genet A 2021;185:2471-6. [PMID: 34031990 DOI: 10.1002/ajmg.a.62252] [Reference Citation Analysis]
86 Zheng L, Hong F, Huang F, Wang W. Inhibition of PI4KIIIα as a Novel Potential Approach for Gaucher Disease Treatment. Neurosci Bull 2021;37:1234-9. [PMID: 34019252 DOI: 10.1007/s12264-021-00704-w] [Reference Citation Analysis]
87 Koto Y, Sakai N, Lee Y, Kakee N, Matsuda J, Tsuboi K, Shimozawa N, Okuyama T, Nakamura K, Narita A, Kobayashi H, Uehara R, Nakamura Y, Kato K, Eto Y. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan. Mol Genet Metab 2021;133:277-88. [PMID: 34090759 DOI: 10.1016/j.ymgme.2021.05.004] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
88 Nakanishi E, Uemura N, Akiyama H, Kinoshita M, Masanori S, Taruno Y, Yamakado H, Matsuzawa SI, Takeda S, Hirabayashi Y, Takahashi R. Impact of Gba2 on neuronopathic Gaucher's disease and α-synuclein accumulation in medaka (Oryzias latipes). Mol Brain 2021;14:80. [PMID: 33971917 DOI: 10.1186/s13041-021-00790-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Abed Rabbo M, Khodour Y, Kaguni LS, Stiban J. Sphingolipid lysosomal storage diseases: from bench to bedside. Lipids Health Dis 2021;20:44. [PMID: 33941173 DOI: 10.1186/s12944-021-01466-0] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
90 Borie R, Crestani B, Guyard A, Lidove O. Interstitial lung disease in lysosomal storage disorders. Eur Respir Rev 2021;30:200363. [PMID: 33927007 DOI: 10.1183/16000617.0363-2020] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
91 Mehta A, Rivero-Arias O, Abdelwahab M, Campbell S, McMillan A, Rolfe MJ, Bright JR, Kuter DJ. Scoring system to facilitate diagnosis of Gaucher disease. Intern Med J 2020;50:1538-46. [PMID: 33174353 DOI: 10.1111/imj.14942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
92 Prasuhn J, Brüggemann N. Genotype-driven therapeutic developments in Parkinson's disease. Mol Med 2021;27:42. [PMID: 33874883 DOI: 10.1186/s10020-021-00281-8] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
93 Cohen Y, Frydman D, Rotem R, Kofman R, Zimran A, Revel-Vilk S, Grisaru-Granovsky S. Risk of postpartum hemorrhage in multiparous women with Gaucher disease: A call for reconsidering enzyme replacement therapy in all pregnant patients. J Inherit Metab Dis 2021. [PMID: 33829536 DOI: 10.1002/jimd.12382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Sieberg CB, Lebel A, Silliman E, Holmes S, Borsook D, Elman I. Left to themselves: Time to target chronic pain in childhood rare diseases. Neurosci Biobehav Rev 2021;126:276-88. [PMID: 33774086 DOI: 10.1016/j.neubiorev.2021.03.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Fan X, Zhao S, Yu C, Wu D, Yan Z, Fan L, Song Y, Wang Y, Li C, Ming Y, Gui B, Niu Y, Li X, Yang X, Luo S, Zhang Q, Zhao X, Pan H, Li M, Xia W, Qiu G, Liu P, Zhang S, Zhang J, Wu Z, Lupski JR, Posey JE, Chen S, Gong C, Wu N; Deciphering Disorders Involving Scoliosis and COmorbidities (DISCO) study. Exome sequencing reveals genetic architecture in patients with isolated or syndromic short stature. J Genet Genomics 2021;48:396-402. [PMID: 34006472 DOI: 10.1016/j.jgg.2021.02.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Weber M, Min SW, Truong T, Hung J, Dale S, Reichelt M, Ubhayakar S, Cain-Hom C, Baca M, Jiang Z, Li Q, Brendza R, Lin H, Kung C, Forrest WF, Quiason-Huynh C, Sandoval W, Chen B, Deng Y, Easton A, Foreman O, Sene A, Bingol B. Ocular phenotypes in a mouse model of impaired glucocerebrosidase activity. Sci Rep 2021;11:6079. [PMID: 33727605 DOI: 10.1038/s41598-021-85528-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
97 Serbian I, Prell E, Fischer C, Deigner HP, Csuk R. n-Propyl 6-amino-2,6-dideoxy-2,2-difluoro-β-d-glucopyranoside is a good inhibitor for the β-galactosidase from E. coli. Med Chem Res 2021;:1-9. [PMID: 33716475 DOI: 10.1007/s00044-021-02715-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Benz J, Rufer AC, Huber S, Ehler A, Hug M, Topp A, Guba W, Hofmann EC, Jagasia R, Rodríguez Sarmiento RM. Novel β-Glucocerebrosidase Activators That Bind to a New Pocket at a Dimer Interface and Induce Dimerization. Angew Chem Int Ed Engl 2021;60:5436-42. [PMID: 33238058 DOI: 10.1002/anie.202013890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Consul N, Javed-Tayyab S, Morani AC, Menias CO, Lubner MG, Elsayes KM. Iron-containing pathologies of the spleen: magnetic resonance imaging features with pathologic correlation. Abdom Radiol (NY) 2021;46:1016-26. [PMID: 32915270 DOI: 10.1007/s00261-020-02709-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Thejeal RF, Wahhab SBA, Saadi NW. Pitfalls in the diagnosis of Gaucher disease in Iraq: A diagnostic experience from a developing country. Pak J Med Sci 2021;37:782-7. [PMID: 34104165 DOI: 10.12669/pjms.37.3.2930] [Reference Citation Analysis]
101 Pasqua T, Rocca C, Giglio A, Angelone T. Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications. J Clin Med 2021;10:721. [PMID: 33673114 DOI: 10.3390/jcm10040721] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
102 Savolainen MJ, Karlsson A, Rohkimainen S, Toppila I, Lassenius MI, Falconi CV, Uusi-Rauva K, Elomaa K. The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland. Mol Genet Metab Rep 2021;27:100725. [PMID: 33604241 DOI: 10.1016/j.ymgmr.2021.100725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Stiles AR, Huggins E, Fierro L, Jung SH, Balwani M, Kishnani PS. The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease. Mol Genet Metab Rep 2021;27:100729. [PMID: 33614410 DOI: 10.1016/j.ymgmr.2021.100729] [Reference Citation Analysis]
104 Moya-Garzon MD, Gomez-Vidal JA, Alejo-Armijo A, Altarejos J, Rodriguez-Madoz JR, Fernandes MX, Salido E, Salido S, Diaz-Gavilan M. Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias. J Pers Med 2021;11:74. [PMID: 33513899 DOI: 10.3390/jpm11020074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
105 Cullufi P, Tabaku M, Velmishi V, Gjikopulli A, Tomori S, Dervishi E, Tako A, Leubauer A, Westenberger A, Cozma C, Beetz C, Bauer P, Wirth S, Rolfs A. Genetic characterization of the Albanian Gaucher disease patient population. JIMD Rep 2021;57:52-7. [PMID: 33473340 DOI: 10.1002/jmd2.12167] [Reference Citation Analysis]
106 Benz J, Rufer AC, Huber S, Ehler A, Hug M, Topp A, Guba W, Hofmann EC, Jagasia R, Rodríguez Sarmiento RM. Novel β‐Glucocerebrosidase Activators That Bind to a New Pocket at a Dimer Interface and Induce Dimerization. Angew Chem 2021;133:5496-502. [DOI: 10.1002/ange.202013890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Mehta A, Ramaswami U, Muenzer J, Giugliani R, Ullrich K, Collin-Histed T, Panahloo Z, Wellhoefer H, Frader J. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide. Orphanet J Rare Dis 2021;16:8. [PMID: 33407729 DOI: 10.1186/s13023-020-01645-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Li F, Lu X, Liu X, Su L, Li X, Chen H. Structural Modification of Benzimidazole-Iminosugars and Their Inhibitory Activities against β -Glycosidases. Chinese Journal of Organic Chemistry 2021;41:3643. [DOI: 10.6023/cjoc202105003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Terranova DA, Giraldo LJM, Idrobo H, Satizabal JM. Molecular Characterization of the GBA Gene in Patients from Southwest of Colombia with Gaucher Disease. J inborn errors metab screen 2021;9:e20200018. [DOI: 10.1590/2326-4594-jiems-2020-0018] [Reference Citation Analysis]
110 Pinto F, Nassone E, Ismail M, Jamisse A, Kubaski F, Brusius-facchin AC, Giugliani R, Madeira L, Fernandes F. Difficulties in the Diagnosis of Gaucher Disease in a Low-Income Country: A Case Report from Mozambique. J inborn errors metab screen 2021;9:e20200022. [DOI: 10.1590/2326-4594-jiems-2020-0022] [Reference Citation Analysis]
111 Kakhlon O, Escriba PV, Akman HO, Weil M. Editorial: Using Small Molecules to Treat Macromolecule Storage Disorders. Front Cell Dev Biol 2020;8:623613. [PMID: 33330518 DOI: 10.3389/fcell.2020.623613] [Reference Citation Analysis]
112 Cole M, Zhorne L, Glykys J. Atypical Presentation of Primary Stabbing Headache in a Patient With Type 3 Gaucher Disease. Pediatr Neurol 2021;116:57-8. [PMID: 33486419 DOI: 10.1016/j.pediatrneurol.2020.12.002] [Reference Citation Analysis]
113 Carubbi F, Barbato A, Burlina AB, Francini F, Mignani R, Pegoraro E, Landini L, De Danieli G, Bruni S, Strazzullo P; Italian Society of Human Nutrition Working Group on Nutrition in Lysosomal Storage Diseases. Nutrition in adult patients with selected lysosomal storage diseases. Nutr Metab Cardiovasc Dis 2021;31:733-44. [PMID: 33589321 DOI: 10.1016/j.numecd.2020.11.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Caputo S, Di Martino S, Cilibrasi V, Tardia P, Mazzonna M, Russo D, Penna I, Summa M, Bertozzi SM, Realini N, Margaroli N, Migliore M, Ottonello G, Liu M, Lansbury P, Armirotti A, Bertorelli R, Ray SS, Skerlj R, Scarpelli R. Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors. J Med Chem 2020;63:15821-51. [PMID: 33290061 DOI: 10.1021/acs.jmedchem.0c01561] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Jongsma MLM, de Waard AA, Raaben M, Zhang T, Cabukusta B, Platzer R, Blomen VA, Xagara A, Verkerk T, Bliss S, Kong X, Gerke C, Janssen L, Stickel E, Holst S, Plomp R, Mulder A, Ferrone S, Claas FHJ, Heemskerk MHM, Griffioen M, Halenius A, Overkleeft H, Huppa JB, Wuhrer M, Brummelkamp TR, Neefjes J, Spaapen RM. The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity 2021;54:132-150.e9. [PMID: 33271119 DOI: 10.1016/j.immuni.2020.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
116 Beasley J, Mccaw P, Zhang H, Young SP, Stiles AR. Combined analysis of plasma or serum glucosylsphingosine and globotriaosylsphingosine by UPLC-MS/MS. Clinica Chimica Acta 2020;511:132-7. [DOI: 10.1016/j.cca.2020.10.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
117 Pallottini V, Pfrieger FW. Understanding and Treating Niemann-Pick Type C Disease: Models Matter. Int J Mol Sci 2020;21:E8979. [PMID: 33256121 DOI: 10.3390/ijms21238979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
118 Turton N, Rutherford T, Thijssen D, Hargreaves IP. Putative adjunct therapies to target mitochondrial dysfunction and oxidative stress in phenylketonuria, lysosomal storage disorders and peroxisomal disorders. Expert Opinion on Orphan Drugs 2020;8:431-44. [DOI: 10.1080/21678707.2020.1850254] [Reference Citation Analysis]
119 Ciana G, Dardis A, Pavan E, Da Riol RM, Biasizzo J, Ferino D, Zanatta M, Boni A, Antonini L, Crichiutti G, Bembi B. In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy. Mol Genet Metab Rep 2020;25:100678. [PMID: 33294373 DOI: 10.1016/j.ymgmr.2020.100678] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Tang C, Jia X, Tang F, Liu S, Jiang X, Zhao X, Sheng H, Peng M, Liu L, Huang Y. Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS/MS. Clin Biochem 2021;87:79-84. [PMID: 33188770 DOI: 10.1016/j.clinbiochem.2020.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
121 Caso-González A, Núñez-Rodríguez J, Nebot-Villacampa MJ, González-Pérez Y, Marín-Gorricho R, Leralta-González C, Obaldia-Alaña C. [Clinical experience with orphan drugs for rare metabolic diseases]. An Pediatr (Engl Ed) 2020:S1695-4033(20)30437-9. [PMID: 33158793 DOI: 10.1016/j.anpedi.2020.09.019] [Reference Citation Analysis]
122 Desplanque M, Bonte MA, Gressier B, Devos D, Chartier-Harlin MC, Belarbi K. Trends in Glucocerebrosides Research: A Systematic Review. Front Physiol 2020;11:558090. [PMID: 33192552 DOI: 10.3389/fphys.2020.558090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Menkovic I, Boutin M, Alayoubi A, Mercier FE, Rivard GÉ, Auray-Blais C. Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach. Int J Mol Sci 2020;21:E7869. [PMID: 33114153 DOI: 10.3390/ijms21217869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
124 Poffenberger CN, Inati S, Tayebi N, Stubblefield BK, Ryan E, Schiffmann R, Sidransky E, Lopez G. EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review. Mol Genet Metab 2020;131:358-63. [PMID: 33183916 DOI: 10.1016/j.ymgme.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
125 von Linstow CU, Gan-Or Z, Brundin P. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. Transl Neurodegener 2020;9:39. [PMID: 33066808 DOI: 10.1186/s40035-020-00218-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
126 Castellan T, Garcia V, Rodriguez F, Fabing I, Shchukin Y, Tran ML, Ballereau S, Levade T, Génisson Y, Dehoux C. Concise asymmetric synthesis of new enantiomeric C-alkyl pyrrolidines acting as pharmacological chaperones against Gaucher disease. Org Biomol Chem 2020;18:7852-61. [PMID: 32975266 DOI: 10.1039/d0ob01522a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
127 Sawada T, Kido J, Sugawara K, Matsumoto S, Takada F, Tsuboi K, Ohtake A, Endo F, Nakamura K. Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening. Mol Genet Genomic Med 2020;8:e1502. [PMID: 33016649 DOI: 10.1002/mgg3.1502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
128 Revel-Vilk S, Fuller M, Zimran A. Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review. Int J Mol Sci 2020;21:E7159. [PMID: 32998334 DOI: 10.3390/ijms21197159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
129 Anderson HE, Taylor MRG. Consequences of treatment for hemophagocytic lymphohistiocytosis in a patient with undiagnosed Gaucher disease Type 1. Am J Med Genet A 2020;182:2988-93. [PMID: 32985097 DOI: 10.1002/ajmg.a.61880] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Di Rocco M, Di Fonzo A, Barbato A, Cappellini MD, Carubbi F, Giona F, Giuffrida G, Linari S, Pession A, Quarta A, Scarpa M, Spada M, Strisciuglio P, Andria G. Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives? Orphanet J Rare Dis 2020;15:262. [PMID: 32967694 DOI: 10.1186/s13023-020-01529-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Madaan P, Bhagwat C, Kesavan S, Saini L, Sankhyan N. Gaze Palsy, Organomegaly, and Inspiratory Stridor: A Diagnostic Triad. Indian J Pediatr 2021;88:1259. [PMID: 32915439 DOI: 10.1007/s12098-020-03489-4] [Reference Citation Analysis]
132 Wu C, Iwamoto T, Hossain MA, Akiyama K, Igarashi J, Miyajima T, Eto Y. A combination of 7-ketocholesterol, lysosphingomyelin and bile acid-408 to diagnose Niemann-Pick disease type C using LC-MS/MS. PLoS One 2020;15:e0238624. [PMID: 32898135 DOI: 10.1371/journal.pone.0238624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
133 Salah NY. Vascular endothelial growth factor (VEGF), tissue inhibitors of metalloproteinase-1 (TIMP-1) and nail fold capillaroscopy changes in children and adolescents with Gaucher disease; relation to residual disease severity. Cytokine 2020;133:155120. [DOI: 10.1016/j.cyto.2020.155120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Greuel A, Trezzi JP, Glaab E, Ruppert MC, Maier F, Jäger C, Hodak Z, Lohmann K, Ma Y, Eidelberg D, Timmermann L, Hiller K, Tittgemeyer M, Drzezga A, Diederich N, Eggers C. GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Mov Disord 2020;35:2201-10. [PMID: 32853481 DOI: 10.1002/mds.28225] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
135 Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev 2021;10:86-98. [PMID: 32851809 DOI: 10.1002/cpdd.865] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
136 Kloska A, Węsierska M, Malinowska M, Gabig-Cimińska M, Jakóbkiewicz-Banecka J. Lipophagy and Lipolysis Status in Lipid Storage and Lipid Metabolism Diseases. Int J Mol Sci 2020;21:E6113. [PMID: 32854299 DOI: 10.3390/ijms21176113] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
137 Roshan Lal T, Seehra GK, Steward AM, Poffenberger CN, Ryan E, Tayebi N, Lopez G, Sidransky E. The natural history of type 2 Gaucher disease in the 21st century: A retrospective study. Neurology 2020;95:e2119-30. [PMID: 32764102 DOI: 10.1212/WNL.0000000000010605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
138 Rozenfeld PA, Crivaro AN, Ormazabal M, Mucci JM, Bondar C, Delpino MV. Unraveling the mystery of Gaucher bone density pathophysiology. Mol Genet Metab 2021;132:76-85. [PMID: 32782168 DOI: 10.1016/j.ymgme.2020.07.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Haarr MB, Lopéz Ó, Pejov L, Fernández-Bolaños JG, Lindbäck E, Sydnes MO. 1,4-Dideoxy-1,4-imino-d-arabinitol (DAB) Analogues Possessing a Hydrazide Imide Moiety as Potent and Selective α-Mannosidase Inhibitors. ACS Omega 2020;5:18507-14. [PMID: 32743229 DOI: 10.1021/acsomega.0c02466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
140 Villasmil ML, Barbosa AD, Cunningham JL, Siniossoglou S, Nickels JT Jr. An Erg11 lanosterol 14-α-demethylase-Arv1 complex is required for Candida albicans virulence. PLoS One 2020;15:e0235746. [PMID: 32678853 DOI: 10.1371/journal.pone.0235746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
141 Tran ML, Génisson Y, Ballereau S, Dehoux C. Second-Generation Pharmacological Chaperones: Beyond Inhibitors. Molecules 2020;25:E3145. [PMID: 32660097 DOI: 10.3390/molecules25143145] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
142 Singh AP, Murray GP, Pandey S. Benign Histiocyte-Rich Pseudotumor Developing Postchemotherapy and Mimicking Residual Disease. Case Rep Pathol 2020;2020:4674103. [PMID: 32695545 DOI: 10.1155/2020/4674103] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
143 Datta S, Rajnish KN, George Priya Doss C, Melvin Samuel S, Selvarajan E, Zayed H. Enzyme therapy: a forerunner in catalyzing a healthy society? Expert Opin Biol Ther 2020;20:1151-74. [PMID: 32597245 DOI: 10.1080/14712598.2020.1787980] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
144 Agarwal PK, Bernard DN, Bafna K, Doucet N. Enzyme dynamics: Looking beyond a single structure. ChemCatChem 2020;12:4704-20. [PMID: 33897908 DOI: 10.1002/cctc.202000665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
145 Lepe-Balsalobre E, Santotoribio JD, Nuñez-Vazquez R, García-Morillo S, Jiménez-Arriscado P, Hernández-Arévalo P, Delarosa-Rodríguez R, Guerrero JM, Macher HC. Genotype/phenotype relationship in Gaucher disease patients. Novel mutation in glucocerebrosidase gene. Clin Chem Lab Med 2020;58:2017-24. [PMID: 32589593 DOI: 10.1515/cclm-2020-0306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
146 Matassini C, Warren J, Wang B, Goti A, Cardona F, Morrone A, Bols M. Imino‐ and Azasugar Protonation Inside Human Acid β‐Glucosidase, the Enzyme that is Defective in Gaucher Disease. Angew Chem 2020;132:10552-5. [DOI: 10.1002/ange.202002850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
147 O'Hara DM, Pawar G, Kalia SK, Kalia LV. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease? Front Neurosci 2020;14:577. [PMID: 32625052 DOI: 10.3389/fnins.2020.00577] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
148 Huh YE, Chiang MSR, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Sardi SP, Scherzer CR. β-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology 2020;95:e685-96. [PMID: 32540937 DOI: 10.1212/WNL.0000000000009989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
149 Crivaro A, Bondar C, Mucci JM, Ormazabal M, Feldman RA, Delpino MV, Rozenfeld PA. Gaucher disease-associated alterations in mesenchymal stem cells reduce osteogenesis and favour adipogenesis processes with concomitant increased osteoclastogenesis. Mol Genet Metab 2020;130:274-82. [PMID: 32536424 DOI: 10.1016/j.ymgme.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Dimitriou E, Moraitou M, Cozar M, Serra-Vinardell J, Vilageliu L, Grinberg D, Mavridou I, Michelakakis H. Gaucher disease: Biochemical and molecular findings in 141 patients diagnosed in Greece. Mol Genet Metab Rep 2020;24:100614. [PMID: 32547927 DOI: 10.1016/j.ymgmr.2020.100614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Loeffler DA, Aasly JO, LeWitt PA, Coffey MP. What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations? J Parkinsons Dis 2019;9:467-88. [PMID: 31322581 DOI: 10.3233/JPD-191630] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
152 Aasly JO. Long-Term Outcomes of Genetic Parkinson's Disease. J Mov Disord 2020;13:81-96. [PMID: 32498494 DOI: 10.14802/jmd.19080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
153 Zhu H, Qiu C, Gryniewicz-Ruzicka CM, Keire DA, Ye H. Multiplexed Comparative Analysis of Intact Glycopeptides Using Electron-Transfer Dissociation and Synchronous Precursor Selection Based Triple-Stage Mass Spectrometry. Anal Chem 2020;92:7547-55. [PMID: 32374158 DOI: 10.1021/acs.analchem.0c00014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Bax BE. Erythrocytes as Carriers of Therapeutic Enzymes. Pharmaceutics 2020;12:E435. [PMID: 32397259 DOI: 10.3390/pharmaceutics12050435] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
155 Pavan E, Ormazabal M, Peruzzo P, Vaena E, Rozenfeld P, Dardis A. CRISPR/Cas9 Editing for Gaucher Disease Modelling. Int J Mol Sci 2020;21:E3268. [PMID: 32380730 DOI: 10.3390/ijms21093268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
156 Trivedi PC, Bartlett JJ, Pulinilkunnil T. Lysosomal Biology and Function: Modern View of Cellular Debris Bin. Cells 2020;9:E1131. [PMID: 32375321 DOI: 10.3390/cells9051131] [Cited by in Crossref: 30] [Cited by in F6Publishing: 60] [Article Influence: 15.0] [Reference Citation Analysis]
157 Soudek L, Siddiqui I, Guerin A, Sondheimer N, Inbar-Feigenberg M, Abuquteish D, Walia JS, Kamath BM, Kehar M. Liver transplantation for Gaucher disease presenting as neonatal cholestasis: Case report and literature review. Pediatr Transplant 2020;24:e13718. [PMID: 32324335 DOI: 10.1111/petr.13718] [Reference Citation Analysis]
158 Matassini C, Warren J, Wang B, Goti A, Cardona F, Morrone A, Bols M. Imino- and Azasugar Protonation Inside Human Acid β-Glucosidase, the Enzyme that is Defective in Gaucher Disease. Angew Chem Int Ed Engl 2020;59:10466-9. [PMID: 32191378 DOI: 10.1002/anie.202002850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
159 Ivanova M. Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases. J Clin Med 2020;9:E1116. [PMID: 32295103 DOI: 10.3390/jcm9041116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
160 Di Martino S, Tardia P, Cilibrasi V, Caputo S, Mazzonna M, Russo D, Penna I, Realini N, Margaroli N, Migliore M, Pizzirani D, Ottonello G, Bertozzi SM, Armirotti A, Nguyen D, Sun Y, Bongarzone ER, Lansbury P, Liu M, Skerlj R, Scarpelli R. Lead Optimization of Benzoxazolone Carboxamides as Orally Bioavailable and CNS Penetrant Acid Ceramidase Inhibitors. J Med Chem 2020;63:3634-64. [PMID: 32176488 DOI: 10.1021/acs.jmedchem.9b02004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
161 Tantawy AAG, Adly AAM, Abdeen MSED, Salah NY. Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients. Neurogenetics 2020;21:159-67. [DOI: 10.1007/s10048-020-00607-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
162 Huang Y, Jia X, Tang C, Liu S, Sheng H, Zhao X, Zeng C, Liu L. High risk screening for Gaucher disease in patients with splenomegaly and/or thrombocytopenia in China: 55 cases identified. Clin Chim Acta 2020;506:22-7. [PMID: 32165122 DOI: 10.1016/j.cca.2020.03.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
163 Alioto AG, Gomez R, Moses J, Paternostro J, Packman S, Packman W. Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease, type 1. Am J Med Genet 2020;182:1130-42. [DOI: 10.1002/ajmg.a.61533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
164 Toffoli M, Vieira SRL, Schapira AHV. Genetic causes of PD: A pathway to disease modification. Neuropharmacology 2020;170:108022. [PMID: 32119885 DOI: 10.1016/j.neuropharm.2020.108022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
165 Rathaur P, Sr KJ. Metabolism and Pharmacokinetics of Phytochemicals in the Human Body. CDM 2020;20:1085-102. [DOI: 10.2174/1389200221666200103090757] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
166 Dubot P, Astudillo L, Therville N, Sabourdy F, Stirnemann J, Levade T, Andrieu-Abadie N. Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers (Basel) 2020;12:E475. [PMID: 32085512 DOI: 10.3390/cancers12020475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
167 Nguyen Y, Stirnemann J, Lautredoux F, Cador B, Bengherbia M, Yousfi K, Hamroun D, Astudillo L, Billette de Villemeur T, Brassier A, Camou F, Dalbies F, Dobbelaere D, Gaches F, Leguy-Seguin V, Masseau A, Pers YM, Pichard S, Serratrice C, Berger MG, Fantin B, Belmatoug N, On Behalf Of The French Evaluation Of Gaucher Disease Treatment Committee. Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry. Int J Mol Sci 2020;21:E1247. [PMID: 32069933 DOI: 10.3390/ijms21041247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
168 Eskes ECB, Sjouke B, Vaz FM, Goorden SMI, van Kuilenburg ABP, Aerts JMFG, Hollak CEM. Biochemical and imaging parameters in acid sphingomyelinase deficiency: Potential utility as biomarkers. Mol Genet Metab 2020;130:16-26. [PMID: 32088119 DOI: 10.1016/j.ymgme.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
169 Hansen L, Husein DM, Gericke B, Hansen T, Pedersen O, Tambe MA, Freeze HH, Naim HY, Henrissat B, Wandall HH, Clausen H, Bennett EP. A mutation map for human glycoside hydrolase genes. Glycobiology 2020;30:500-15. [PMID: 32039448 DOI: 10.1093/glycob/cwaa010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
170 Mhanni A, Boutin M, Stockl F, Johnston J, Barnes J, Duerksen D, Zimmer L, Auray-Blais C, Rockman-Greenberg C. Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment. Diagnostics (Basel) 2020;10:E69. [PMID: 31991859 DOI: 10.3390/diagnostics10020069] [Reference Citation Analysis]
171 Basgalupp SP, Siebert M, Ferreira C, Behringer S, Spiekerkoetter U, Hannibal L, Schwartz IVD. Assessment of cellular cobalamin metabolism in Gaucher disease. BMC Med Genet 2020;21:12. [PMID: 31931749 DOI: 10.1186/s12881-020-0947-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
172 Schiffer V, Santiago-Mujika E, Flunkert S, Schmidt S, Farcher M, Loeffler T, Schilcher I, Posch M, Neddens J, Sun Y, Kehr J, Hutter-Paier B. Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease. PLoS One 2020;15:e0227077. [PMID: 31929594 DOI: 10.1371/journal.pone.0227077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
173 Hanss Z, Boussaad I, Jarazo J, Schwamborn JC, Krüger R. Quality Control Strategy for CRISPR-Cas9-Based Gene Editing Complicated by a Pseudogene. Front Genet 2019;10:1297. [PMID: 31998363 DOI: 10.3389/fgene.2019.01297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
174 Starosta RT, Vairo FPE, Dornelles AD, Basgalupp SP, Siebert M, Pedroso MLA, Cerski CTS, Álvares-da-Silva MR, Schwartz IVD. Liver involvement in patients with Gaucher disease types I and III. Mol Genet Metab Rep 2020;22:100564. [PMID: 32099816 DOI: 10.1016/j.ymgmr.2019.100564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
175 Seehra GK, Eghbali A, Sidransky E, FitzGibbon E. White vitreous opacities in five patients with Gaucher disease type 3. Am J Med Genet A 2020;182:808-12. [PMID: 31898869 DOI: 10.1002/ajmg.a.61479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
176 Boof M, Halabi A, Ufer M, Dingemanse J. Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects. Eur J Clin Pharmacol 2020;76:431-7. [DOI: 10.1007/s00228-019-02808-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
177 Kałużna M, Trzeciak I, Ziemnicka K, Machaczka M, Ruchała M. Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review. Orphanet J Rare Dis 2019;14:275. [PMID: 31791361 DOI: 10.1186/s13023-019-1211-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
178 Gawad Tantawy AA, Moneam Adly AA, Madkour SS, Salah El‐din NY. Pulmonary manifestations in young Gaucher disease patients: Phenotype‐genotype correlation and radiological findings. Pediatr Pulmonol 2019;55:441-8. [DOI: 10.1002/ppul.24544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
179 Sulaiman RA. Inherited metabolic disorders and dyslipidaemia. J Clin Pathol 2020;73:384-90. [PMID: 31757783 DOI: 10.1136/jclinpath-2019-205910] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Zaretsky L, Zeid N, Naik H, Alcalay RN, Balwani M. Knowledge and attitudes of Parkinson’s disease risk in the Gaucher population. Jrnl of Gene Coun 2019;29:105-11. [DOI: 10.1002/jgc4.1185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
181 Xicoy H, Peñuelas N, Vila M, Laguna A. Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows. Cells 2019;8:E1317. [PMID: 31731485 DOI: 10.3390/cells8111317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
182 Jaszczyk J, Li S, Cocaud C, Nicolas C, Martin OR. A practical approach to Dideoxy-1,4- and 1,5-iminopentitols from protected sugar hemiacetals. Carbohydr Res 2019;486:107855. [PMID: 31704572 DOI: 10.1016/j.carres.2019.107855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
183 Johnson PH, Weinreb NJ, Cloyd JC, Tuite PJ, Kartha RV. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies. Mol Genet Metab 2020;129:35-46. [PMID: 31761523 DOI: 10.1016/j.ymgme.2019.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
184 Dinur T, Zimran A, Becker-Cohen M, Arkadir D, Cozma C, Hovakimyan M, Oppermann S, Demuth L, Rolfs A, Revel-Vilk S. Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease. J Clin Med 2019;8:E1662. [PMID: 31614613 DOI: 10.3390/jcm8101662] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
185 Marzouk I, Deghady A, Omar OM, Ashour RS. Hyperimmunoglobulinemia and IgG Subclass Abnormalities in Children With Gaucher Disease. Journal of Pediatric Hematology/Oncology 2019;41:e416-20. [DOI: 10.1097/mph.0000000000001574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
186 Serratrice C, Cherin P, Lidove O, Noel E, Masseau A, Leguy-Seguin V, Jaussaud R, Marie I, Lavigne C, Maillot F. Coagulation Parameters in Adult Patients With Type-1 Gaucher Disease. J Hematol 2019;8:121-4. [PMID: 32300455 DOI: 10.14740/jh543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Deriaz S, Serratrice C, Lidove O, Noël E, Masseau A, Lorcerie B, Jaussaud R, Marie I, Lavigne C, Cabane J, Kaminsky P, Chérin P, Maillot F; pour le groupe de travail 'médecine interne-maladies rares'. [Diagnostic journey of type 1 Gaucher Disease patients: A survey including internists and hematologists]. Rev Med Interne 2019;40:778-84. [PMID: 31500934 DOI: 10.1016/j.revmed.2019.07.011] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Palhegyi AM, Seranova E, Dimova S, Hoque S, Sarkar S. Biomedical Implications of Autophagy in Macromolecule Storage Disorders. Front Cell Dev Biol 2019;7:179. [PMID: 31555645 DOI: 10.3389/fcell.2019.00179] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
189 Gigliobianco MR, Di Martino P, Deng S, Casadidio C, Censi R. New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System. CPD 2019;25:1933-50. [DOI: 10.2174/1381612825666190708213159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
190 Tseng SY, Niu DM, Chu TH, Yeh YC, Huang MH, Yang TF, Liao HC, Chiang CC, Ho HC, Soong WJ, Yang CF. Very rare condition of multiple Gaucheroma: A case report and review of the literature. Mol Genet Metab Rep 2019;20:100489. [PMID: 31341788 DOI: 10.1016/j.ymgmr.2019.100489] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Faucher B, Seguier J, Swiader L, Cuquemelle C, Cerutti D, Ebbo M. [Gaucher Disease type 1 mimicking immune thrombocytopenia: Role of hyperferritinemia and hypergammaglobulinemia in the initial evaluation of an isolated thrombopenia]. Rev Med Interne 2019;40:680-3. [PMID: 31213336 DOI: 10.1016/j.revmed.2019.05.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
192 Crivaro AN, Mucci JM, Bondar CM, Ormazabal ME, Ceci R, Simonaro C, Rozenfeld PA. Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease. PLoS One 2019;14:e0217780. [PMID: 31150494 DOI: 10.1371/journal.pone.0217780] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
193 Drews K, Calgi MP, Harrison WC, Drews CM, Costa-Pinheiro P, Shaw JJP, Jobe KA, Nelson EA, Han JD, Fox T, White JM, Kester M. Glucosylceramidase Maintains Influenza Virus Infection by Regulating Endocytosis. J Virol 2019;93:e00017-19. [PMID: 30918081 DOI: 10.1128/JVI.00017-19] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
194 Wei M, Han A, Wei L, Ma L. A Neonatal Case With Perinatal Lethal Gaucher Disease Associated With Missense G234E and H413P Heterozygous Mutations. Front Pediatr 2019;7:201. [PMID: 31192173 DOI: 10.3389/fped.2019.00201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
195 Crisafulli S, Sultana J, Ingrasciotta Y, Addis A, Cananzi P, Cavagna L, Conter V, D’angelo G, Ferrajolo C, Mantovani L, Pastorello M, Scondotto S, Trifirò G. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opinion on Drug Safety 2019;18:497-509. [DOI: 10.1080/14740338.2019.1614165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
196 Righi M, Belleri M, Presta M, Giacomini A. Quantification of 3D Brain Microangioarchitectures in an Animal Model of Krabbe Disease. Int J Mol Sci 2019;20:E2384. [PMID: 31091708 DOI: 10.3390/ijms20102384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
197 Wilke MVMB, Dornelles AD, Schuh AS, Vairo FP, Basgalupp SP, Siebert M, Nalin T, Piltcher OB, Schwartz IVD. Evaluation of the frequency of non-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1. Orphanet J Rare Dis 2019;14:103. [PMID: 31077260 DOI: 10.1186/s13023-019-1079-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
198 Tseng SY, Niu DM, Chu TH, Yeh YC, Huang MH, Yang TF, Liao HC, Chiang CC, Ho HC, Soong WJ, Yang CF. Very rare condition of multiple Gaucheroma: A case report and review of the literature. Mol Genet Metab Rep 2019;20:100473. [PMID: 31193028 DOI: 10.1016/j.ymgmr.2019.100473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
199 Nguyen Y, Stirnemann J, Belmatoug N. La maladie de Gaucher : quand y penser ? La Revue de Médecine Interne 2019;40:313-22. [DOI: 10.1016/j.revmed.2018.11.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
200 Riboldi GM, Di Fonzo AB. GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 2019;8:E364. [PMID: 31010158 DOI: 10.3390/cells8040364] [Cited by in Crossref: 58] [Cited by in F6Publishing: 83] [Article Influence: 19.3] [Reference Citation Analysis]
201 Ma G, Liu H, Du M, Zhang G, Lin Y, Ge Y, Wang M, Jin G, Zhao Q, Chu H, Gong W, Zhang Z. A genetic variation in the CpG island of pseudogene GBAP1 promoter is associated with gastric cancer susceptibility. Cancer 2019;125:2465-73. [PMID: 30951202 DOI: 10.1002/cncr.32081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
202 Mohammad SS, Paget SP, Dale RC. Current therapies and therapeutic decision making for childhood-onset movement disorders. Mov Disord 2019;34:637-56. [PMID: 30919519 DOI: 10.1002/mds.27661] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
203 Chuang WL, Pacheco J, Hoxha D, Sanderink G, Sung C. Galactosylsphingosine does not interfere with the quantitation of plasma glucosylsphingosine levels in Gaucher patients. Clin Chim Acta 2019;494:48-51. [PMID: 30858093 DOI: 10.1016/j.cca.2019.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
204 Oliveri B, González D, Quiroga F, Silva C, Rozenfeld P. A Comprehensive Study of Bone Manifestations in Adult Gaucher Disease Type 1 Patients in Argentina. Calcif Tissue Int 2019;104:650-7. [DOI: 10.1007/s00223-019-00536-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
205 Wątek M, Piktel E, Wollny T, Durnaś B, Fiedoruk K, Lech-Marańda E, Bucki R. Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development. Int J Mol Sci 2019;20:E843. [PMID: 30781349 DOI: 10.3390/ijms20040843] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
206 Chadha J, Sahai T, Schwimmer J, Shani D. A 30-Year-Old Carrier of Gaucher Disease with Multiple Myeloma. Case Rep Oncol Med 2019;2019:6469196. [PMID: 30906609 DOI: 10.1155/2019/6469196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
207 Baruteau J, Waddington SN. Fetal gene therapy for neurodegenerative lysosomal storage diseases. J Inherit Metab Dis 2019;42:391-3. [PMID: 30715735 DOI: 10.1002/jimd.12018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Gatto EM, Da Prat G, Etcheverry JL, Drelichman G, Cesarini M. Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency. Brain Sci 2019;9:E30. [PMID: 30717266 DOI: 10.3390/brainsci9020030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
209 Zhang T, de Waard AA, Wuhrer M, Spaapen RM. The Role of Glycosphingolipids in Immune Cell Functions. Front Immunol 2019;10:90. [PMID: 30761148 DOI: 10.3389/fimmu.2019.00090] [Cited by in Crossref: 37] [Cited by in F6Publishing: 51] [Article Influence: 12.3] [Reference Citation Analysis]
210 Jaffe DH, Flaks-Manov N, Benis A, Gabay H, DiBonaventura M, Rosenbaum H, Joseph A, Bachrach A, Leventer-Roberts M. Population-based cohort of 500 patients with Gaucher disease in Israel. BMJ Open 2019;9:e024251. [PMID: 30670517 DOI: 10.1136/bmjopen-2018-024251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
211 Faverio P, Stainer A, De Giacomi F, Gasperini S, Motta S, Canonico F, Pieruzzi F, Monzani A, Pesci A, Biondi A. Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases. Int J Mol Sci 2019;20:E327. [PMID: 30650529 DOI: 10.3390/ijms20020327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
212 Akhter S, Kaur H, Agrawal P, Raghava GPS. RareLSD: a manually curated database of lysosomal enzymes associated with rare diseases. Database (Oxford) 2019;2019:baz112. [PMID: 31688938 DOI: 10.1093/database/baz112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
213 Abdel Razek AAK, Barakat T, Ali K. Assessment of Liver and Spleen in Children With Gaucher Disease Type 1 With Chemical Shift Imaging: . Journal of Computer Assisted Tomography 2019;43:183-6. [DOI: 10.1097/rct.0000000000000817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
214 Gupta P, Pastores G. Pharmacological treatment of pediatric Gaucher disease. Expert Rev Clin Pharmacol 2018;11:1183-94. [PMID: 30444430 DOI: 10.1080/17512433.2018.1549486] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
215 D'Arco F, Hanagandi P, Ganau M, Krishnan P, Taranath A. Neuroimaging Findings in Lysosomal Disorders: 2018 Update. Top Magn Reson Imaging 2018;27:259-74. [PMID: 30086111 DOI: 10.1097/RMR.0000000000000174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
216 Rugen MD, Vernet MMJL, Hantouti L, Soenens A, Andriotis VME, Rejzek M, Brett P, van den Berg RJBHN, Aerts JMFG, Overkleeft HS, Field RA. A chemical genetic screen reveals that iminosugar inhibitors of plant glucosylceramide synthase inhibit root growth in Arabidopsis and cereals. Sci Rep 2018;8:16421. [PMID: 30401902 DOI: 10.1038/s41598-018-34749-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
217 Hirabayashi T, Murakami M, Kihara A. The role of PNPLA1 in ω-O-acylceramide synthesis and skin barrier function. Biochim Biophys Acta Mol Cell Biol Lipids 2019;1864:869-79. [PMID: 30290227 DOI: 10.1016/j.bbalip.2018.09.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
218 Sheth J, Pancholi D, Mistri M, Nath P, Ankleshwaria C, Bhavsar R, Puri R, Phadke S, Sheth F. Biochemical and molecular characterization of adult patients with type I Gaucher disease and carrier frequency analysis of Leu444Pro - a common Gaucher disease mutation in India. BMC Med Genet 2018;19:178. [PMID: 30285649 DOI: 10.1186/s12881-018-0687-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
219 Qureshi YH, Patel VM, Berman DE, Kothiya MJ, Neufeld JL, Vardarajan B, Tang M, Reyes-Dumeyer D, Lantigua R, Medrano M, Jiménez-Velázquez IJ, Small SA, Reitz C. An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect. Mol Cell Biol 2018;38:e00011-18. [PMID: 30037983 DOI: 10.1128/MCB.00011-18] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
220 Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E. Exploring genetic modifiers of Gaucher disease: The next horizon. Hum Mutat 2018;39:1739-51. [PMID: 30098107 DOI: 10.1002/humu.23611] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
221 Yoshihara T, Satake H, Nishie T, Okino N, Hatta T, Otani H, Naruse C, Suzuki H, Sugihara K, Kamimura E, Tokuda N, Furukawa K, Fururkawa K, Ito M, Asano M. Lactosylceramide synthases encoded by B4galt5 and 6 genes are pivotal for neuronal generation and myelin formation in mice. PLoS Genet 2018;14:e1007545. [PMID: 30114188 DOI: 10.1371/journal.pgen.1007545] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
222 Zimran A, Dinur T, Revel-Vilk S, Akkerman EM, van Dussen L, Hollak CEM, Maayan H, Altarescu G, Chertkoff R, Maas M. Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa. J Inherit Metab Dis 2018;41:1259-65. [PMID: 30066229 DOI: 10.1007/s10545-018-0195-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
223 Naphatsamon U, Ohashi T, Misaki R, Fujiyama K. The Production of Human β-Glucocerebrosidase in Nicotiana benthamiana Root Culture. Int J Mol Sci 2018;19:E1972. [PMID: 29986415 DOI: 10.3390/ijms19071972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
224 Hassan S, Lopez G, Stubblefield BK, Tayebi N, Sidransky E. Alleles with more than one mutation can complicate genotype/phenotype studies in Mendelian disorders: Lessons from Gaucher disease. Mol Genet Metab 2018;125:1-3. [PMID: 29980418 DOI: 10.1016/j.ymgme.2018.06.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
225 Oliver R, Sallam AB, Uwaydat SH. Retinal Deposits in a Young Woman. JAMA Ophthalmol 2018;136:708. [DOI: 10.1001/jamaophthalmol.2017.5208] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
226 Bingol B. Autophagy and lysosomal pathways in nervous system disorders. Mol Cell Neurosci 2018;91:167-208. [PMID: 29729319 DOI: 10.1016/j.mcn.2018.04.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
227 Mena-Barragán T, García-Moreno MI, Sevšek A, Okazaki T, Nanba E, Higaki K, Martin NI, Pieters RJ, Fernández JMG, Mellet CO. Probing the Inhibitor versus Chaperone Properties of sp²-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease. Molecules 2018;23:E927. [PMID: 29673163 DOI: 10.3390/molecules23040927] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
228 Chen Y, Sud N, Hettinghouse A, Liu CJ. Molecular regulations and therapeutic targets of Gaucher disease. Cytokine Growth Factor Rev 2018;41:65-74. [PMID: 29699937 DOI: 10.1016/j.cytogfr.2018.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
229 Le Peillet D, Prendki V, Trombert V, Laffitte E, Assal F, Reny JL, Serratrice C. Type I Gaucher disease with bullous pemphigoid and Parkinson disease: A case report. Medicine (Baltimore) 2018;97:e0188. [PMID: 29595653 DOI: 10.1097/MD.0000000000010188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
230 Zhao X, Brusadelli MG, Sauter S, Butsch Kovacic M, Zhang W, Romick-Rosendale LE, Lambert PF, Setchell KDR, Wells SI. Lipidomic Profiling Links the Fanconi Anemia Pathway to Glycosphingolipid Metabolism in Head and Neck Cancer Cells. Clin Cancer Res 2018;24:2700-9. [PMID: 29530934 DOI: 10.1158/1078-0432.CCR-17-3686] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
231 Serai SD, Naidu AP, Andrew Burrow T, Prada CE, Xanthakos S, Towbin AJ. Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients. Molecular Genetics and Metabolism 2018;123:357-63. [DOI: 10.1016/j.ymgme.2017.10.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
232 López de Frutos L, Cebolla JJ, Irún P, Köhler R, Giraldo P. The erythrocyte osmotic resistance test as screening tool for cholesterol-related lysosomal storage diseases. Clin Chim Acta 2018;480:161-5. [PMID: 29447902 DOI: 10.1016/j.cca.2018.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
233 Wegner MS, Gruber L, Mattjus P, Geisslinger G, Grösch S. The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1). BMC Cancer 2018;18:153. [PMID: 29409484 DOI: 10.1186/s12885-018-4084-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
234 Moskot M, Bocheńska K, Jakóbkiewicz-Banecka J, Banecki B, Gabig-Cimińska M. Abnormal Sphingolipid World in Inflammation Specific for Lysosomal Storage Diseases and Skin Disorders. Int J Mol Sci 2018;19:E247. [PMID: 29342918 DOI: 10.3390/ijms19010247] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
235 Gámez A, Yuste-checa P, Brasil S, Briso-montiano Á, Desviat L, Ugarte M, Pérez-cerdá C, Pérez B. Protein misfolding diseases: Prospects of pharmacological treatment: GÁMEZ et al. Clin Genet 2018;93:450-8. [DOI: 10.1111/cge.13088] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
236 Ferrari C, Nacmias B, Sorbi S. The diagnosis of dementias: a practical tool not to miss rare causes. Neurol Sci 2018;39:615-27. [PMID: 29198043 DOI: 10.1007/s10072-017-3206-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
237 Schussler E, Yang A, Lyons JJ, Milner JD, Wang J. Persistent tryptase elevation in a patient with Gaucher disease. J Allergy Clin Immunol Pract 2018;6:697-9. [PMID: 29033258 DOI: 10.1016/j.jaip.2017.08.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
238 Beaton B, Monzón JLS, Hughes DA, Pastores GM. Gaucher disease: risk stratification and comorbidities. Expert Opinion on Orphan Drugs 2017;5:839-46. [DOI: 10.1080/21678707.2017.1385455] [Reference Citation Analysis]
239 Lloyd-Smith Sequeira A, Rizzo JR, Rucker JC. Clinical Approach to Supranuclear Brainstem Saccadic Gaze Palsies. Front Neurol 2017;8:429. [PMID: 28878733 DOI: 10.3389/fneur.2017.00429] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
240 Tsurumaki H, Katano H, Sato K, Imai R, Niino S, Hirabayashi Y, Ichikawa S. WP1066, a small molecule inhibitor of the JAK/STAT3 pathway, inhibits ceramide glucosyltransferase activity. Biochem Biophys Res Commun 2017;491:265-70. [PMID: 28739255 DOI: 10.1016/j.bbrc.2017.07.115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
241 Rigante D, Cipolla C, Basile U, Gulli F, Savastano MC. Overview of immune abnormalities in lysosomal storage disorders. Immunol Lett 2017;188:79-85. [PMID: 28687233 DOI: 10.1016/j.imlet.2017.07.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
242 Weinreb NJ. Encore! Oral therapy for type 1 Gaucher disease. Blood 2017;129:2337-8. [PMID: 28450571 DOI: 10.1182/blood-2017-02-769034] [Reference Citation Analysis]